184042-58-8 Usage
Chemical structure
A piperazine ring with a 2'-fluoroethyl and tert-butyloxycarbonyl groups attached to it.
Molecular weight
Approximately 219.28 g/mol
Functional groups
Piperazine ring, 2'-fluoroethyl group, and tert-butyloxycarbonyl group
Appearance
Typically a solid or crystalline substance
Solubility
Soluble in organic solvents such as methanol, ethanol, and dimethyl sulfoxide (DMSO)
Stability
Stable under normal temperature and pressure conditions
Reactivity
Can undergo various chemical reactions, such as substitution, addition, and elimination reactions
Pharmaceutical applications
Building block in the synthesis of pharmaceutical compounds
Target disorders
Central nervous system disorders, such as depression, anxiety, and schizophrenia
Antipsychotic potential
Interaction with dopamine receptors and other neurotransmitter systems
Synthesis
Can be synthesized through various chemical reactions, such as condensation, substitution, or addition reactions
Purity
Typically characterized by techniques like high-performance liquid chromatography (HPLC) or gas chromatography-mass spectrometry (GC-MS)
Safety
Handle with care, as it may have potential hazards depending on its concentration and exposure
Storage
Store in a cool, dry place, away from direct sunlight and moisture, and in a sealed container to prevent degradation or contamination.
Check Digit Verification of cas no
The CAS Registry Mumber 184042-58-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,4,0,4 and 2 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 184042-58:
(8*1)+(7*8)+(6*4)+(5*0)+(4*4)+(3*2)+(2*5)+(1*8)=128
128 % 10 = 8
So 184042-58-8 is a valid CAS Registry Number.
184042-58-8Relevant articles and documents
Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5)
Chekol, Rufael,Gheysens, Olivier,Ahamed, Muneer,Cleynhens, Jan,Pokreisz, Peter,Vanhoof, Greet,Janssens, Stefan,Verbruggen, Alfons,Bormans, Guy
supporting information, p. 486 - 496 (2017/04/26)
The cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) plays an important role in various pathologies including pulmonary arterial hypertension and cardiomyopathy. PDE5 represents an important therapeutic and/or prognostic targ
GLYCINE COMPOUND
-
Page/Page column 23, (2012/07/28)
[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.
PURINE COMPOUNDS
-
Page/Page column 10, (2011/10/13)
A compound of the formula: and pharmaceutical compositions for the treatment or prevention of pain.